The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The importance of treatment intensity in frail and elderly patients with multiple myeloma
Siobhan Glavey, MD, PhD, Royal College of Surgeons in Ireland, Dublin, Ireland, highlights the importance of treatment intensity for frail and elderly patients with multiple myeloma. By looking over 10 years of real-world data, Prof. Glavey has observed that elderly patients with multiple myeloma treated over a longer period have better overall survival (OS) and progression-free survival (PFS) of the disease. This suggests that multiple myeloma treatment is well tolerated by elderly patients and maintaining these patients on consistent regimens is key to increase their survival. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
